Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
about
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVProfile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to dateEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEfficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-upDolutegravir: clinical efficacy and role in HIV therapy.Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.Epidemiology and management of antiretroviral-associated cardiovascular disease.No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic ReviewBrief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.Dolutegravir.Dolutegravir: first global approval.Emerging antiretroviral drugs.Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.Dolutegravir: an exciting new kid on the block.Integrase strand transfer inhibitors in the management of HIV-positive individuals.Drug safety profile of integrase strand transfer inhibitors.Dolutegravir for the treatment of adult patients with HIV-1 infection.Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.Dolutegravir, abacavir and lamivudine as HIV therapy.Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults.Integrase Strand Transfer Inhibitors in HIV Therapy.Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.The preclinical discovery and development of dolutegravir for the treatment of HIV.HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity.Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.Abacavir + dolutegravir + lamivudine for the treatment of HIV.Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient.Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
P2860
Q26799712-0B4052CC-7D3D-492B-A60A-6F525638BAC9Q28079025-CF5BF78B-CF1E-4181-B45F-C4FAC0793937Q28081266-CF9D6274-47E5-427F-BF8B-7E9F32F19908Q28538860-1BF994BF-AF14-4C9A-9B99-7F3C10C8A130Q33725024-0C88226D-965D-44BE-99DB-3E179C123478Q33878754-3AB71910-E2B0-4714-8A24-7AD76C62CB73Q34726183-15F36C96-DB9F-4E14-A479-5BDB0DD97AFAQ35021555-182FAE5D-5F88-4192-9811-88AA6B5384F3Q35338096-CC94D7C5-8E57-4931-B79F-EB5323E2B3EDQ36083734-68094909-E08B-4D50-8A8E-EF015A7B3D89Q36162401-85B19AE0-9415-4B72-BC06-01078411D2DCQ36282716-D18FE2B6-61DD-4113-8B4F-C1E87B8CF1B9Q37614157-498C6F0F-6C2B-4EC8-AF6E-808FA48607B2Q38139885-C7E5A16F-64EC-4921-87E1-5F145B3B1E85Q38167382-4FE90F5F-4427-4B7F-B7EF-2BC7FF5E69A2Q38172029-061D44F8-C65E-4331-847A-D0729E12C385Q38180458-3CFDFF56-48FA-4891-BB04-C5267C48539EQ38192022-B2B25208-C685-4DBD-983E-342281307652Q38193524-BCEF3654-1814-44DB-90AA-A19FAE199E64Q38201520-8EECE90B-C5DA-4F8B-B8B2-F535FCA7F71BQ38203844-B25693CC-0E5C-4FFB-88F4-7022EEF1F74AQ38206232-D4C3BC77-AA51-46AD-AF78-79EC90DF4A1BQ38227491-3F32A675-6798-4652-A6CF-4028A7194508Q38240974-2D2B7325-ADEE-4619-993A-0F120E014725Q38263322-DADD24A7-2284-4C9A-A2A0-16A19E949CAFQ38367106-8E7FD990-7E9A-4FCC-A593-C5C4E5E74593Q38541809-C47C833A-D251-4989-9535-8796762F513FQ38620489-9FD9858E-1DB9-4FB7-B778-2C0A1B49FB68Q38637998-4935B2CC-E05F-4BC5-9A9E-836E762F6869Q38662696-C23A3792-7DDF-40A3-97BE-7DC1E19F7BA9Q38686953-3B31F66C-1908-4F9D-BA74-6BDC88DB62ADQ38906639-451986C2-5EDB-4347-9EED-03F44B93CB9AQ38943015-3EC9B0A4-E58E-44F9-B8A7-C7401221F7C9Q38951349-3FE104E4-9B30-4DB8-AC35-6094FB992FF6Q40366201-ACFC3FC0-6FDE-44DD-A71E-6CA567311C82Q40446339-4D2877F3-7310-408B-BFFE-2B07092EC7C3Q40682190-70A34ED7-8000-4457-BEEA-4E73FCE24D4AQ40707619-41A1BA97-6EF5-49B4-A618-BE6AB36B9FBBQ46865574-17A00017-26DA-4C54-9706-1B4B96D90AF9Q47800916-9769A289-21E4-4B65-9EEE-75225EBA69FD
P2860
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dolutegravir in antiretroviral ...... randomized dose-ranging study
@en
type
label
Dolutegravir in antiretroviral ...... randomized dose-ranging study
@en
prefLabel
Dolutegravir in antiretroviral ...... randomized dose-ranging study
@en
P2093
P2860
P50
P1433
P1476
Dolutegravir in antiretroviral ...... randomized dose-ranging study
@en
P2093
Eugene Voronin
Franco Felizarta
Hans-Jürgen Stellbrink
Jacques Reynes
Marty St Clair
Nancy Flack
SPRING-1 Team
Sherene Min
Steve Almond
P2860
P304
P356
10.1097/QAD.0B013E3283612419
P407
P577
2013-07-01T00:00:00Z